What happened with SENS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Senseonics helps people with diabetes continuously monitor glucose using Eversense. A healthcare professional places a long-lasting sensor under the skin; a removable, rechargeable transmitter sends readings and alerts to a mobile app. Nearly all revenue comes from Eversense sales in the United States and Europe, and continued use requires replacement sensors.
The company mainly sells through distributors and fulfillment partners that supply prescribed systems to healthcare providers and patients and bill insurers. It also sells through consignment arrangements with healthcare providers and sometimes earns revenue from sensor insertion and removal procedures. Adoption depends heavily on insurance covering both the device and those procedures, as well as providers being available to perform them.
Ascensia was previously its main buyer and exclusive distributor. Senseonics has taken over U.S. commercialization, while Ascensia continues non-exclusive sales and marketing during the transition in parts of Europe. European transfers depend on local agreements, tender requirements and regulatory conditions. Senseonics also relies entirely on contract manufacturers, with some materials principally coming from a single supplier. It can market products only where it has the required regulatory authorization, and product changes may need further approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Senseonics’ results hinge on insured patients adopting Eversense and its takeover of commercialization from Ascensia, which remains involved in the European transition.
Dexcom competes with Senseonics’ Eversense for diabetes patients and the clinicians prescribing continuous glucose monitors, while insurance reimbursement helps determine Eversense uptake. Watch Dexcom’s G6 and G7: neither requires users to calibrate the device, a convenience Eversense must compete against.
Abbott’s FreeStyle Libre competes directly with Senseonics’ Eversense for people choosing a glucose-monitoring system, with reimbursement important to Eversense sales. Watch Libre 2 and 3’s integration with insulin pumps: Senseonics expects competition from connected monitoring and insulin delivery to increase.
Medtronic competes with Senseonics’ Eversense for patients and prescribing clinicians by selling glucose monitors alongside insulin pumps and diabetes supplies. Its diabetes-product launches are worth watching for changes in monitoring accuracy, convenience and alerts—the features Senseonics identifies as key to Eversense’s competitiveness.
Abbott Laboratories earningsABT
Abbott’s report will show whether Libre’s insulin-pump connections are strengthening its appeal to patients and prescribers, making it harder for Eversense to win users.
Watch what Abbott reports about Libre demand and its integration with insulin pumps. Stronger demand and broader integration would suggest patients and clinicians value connected monitoring and treatment, making Eversense harder to prescribe; weaker demand or limited progress would mean less pressure from this feature.
Fed Interest Rate Decision
The Fed’s decision tracks the cost of borrowing across the economy; higher rates can raise Senseonics’ floating loan interest and make the additional financing it needs for Eversense operations more costly or harder to secure.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher-than-expected rates could increase interest paid on Senseonics’ floating-rate loans and make financing to support Eversense operations costlier or harder to obtain.
If it comes in below expectations
Lower-than-expected rates could reduce interest paid on Senseonics’ floating-rate loans and ease the cost or availability pressures on financing for Eversense operations.
Senseonics Holdings, Inc. earningsThis company
Senseonics Holdings’ report will show whether Eversense sales and gross profit are keeping pace with the cost of taking over U.S. commercialization.
Read quarterly product revenue and gross margin together, then compare them with selling, general and administrative expense. Rising revenue and margin would mean sales are contributing more toward the cost of taking over U.S. selling; revenue growth without margin improvement, alongside higher expenses, would mean the commercial buildout is still running ahead of its returns.
